BACKGROUND AND OBJECTIVES: Traumatic brain injury (TBI) affects millions worldwide and is without effective treatment. One area that is attracting growing interest is the use of transcranial low-level laser therapy (LLLT) to treat TBI. The fact that near-infrared light can penetrate into the brain would allow non-invasive treatment to be carried out with a low likelihood of treatment-related adverse events. LLLT may treat TBI by increasing respiration in the mitochondria, causing activation of transcription factors, reducing inflammatory mediators and oxidative stress, and inhibiting apoptosis. STUDY DESIGN/ MATERIALS AND METHODS: We tested LLLT in a mouse model of closed-head TBI produced by a controlled weight drop onto the skull. Mice received a single treatment with continuous-wave 665, 730, 810, or 980 nm lasers (36 J/cm(2) delivered at 150 mW/cm(2)) 4-hour post-TBI and were followed up by neurological performance testing for 4 weeks. RESULTS: Mice with moderate-to-severe TBI treated with 665 and 810 nm laser (but not with 730 or 980 nm) had a significant improvement in Neurological Severity Score that increased over the course of the follow-up compared to sham-treated controls. Morphometry of brain sections showed a reduction in small deficits in 665 and 810 nm laser treated mouse brains at 28 days. CONCLUSIONS: The effectiveness of 810 nm agrees with previous publications, and together with the effectiveness of 660 nm and non-effectiveness of 730 and 980 nm can be explained by the absorption spectrum of cytochrome oxidase, the candidate mitochondrial chromophore in transcranial LLLT.
BACKGROUND AND OBJECTIVES:Traumatic brain injury (TBI) affects millions worldwide and is without effective treatment. One area that is attracting growing interest is the use of transcranial low-level laser therapy (LLLT) to treat TBI. The fact that near-infrared light can penetrate into the brain would allow non-invasive treatment to be carried out with a low likelihood of treatment-related adverse events. LLLT may treat TBI by increasing respiration in the mitochondria, causing activation of transcription factors, reducing inflammatory mediators and oxidative stress, and inhibiting apoptosis. STUDY DESIGN/ MATERIALS AND METHODS: We tested LLLT in a mouse model of closed-head TBI produced by a controlled weight drop onto the skull. Mice received a single treatment with continuous-wave 665, 730, 810, or 980 nm lasers (36 J/cm(2) delivered at 150 mW/cm(2)) 4-hour post-TBI and were followed up by neurological performance testing for 4 weeks. RESULTS:Mice with moderate-to-severe TBI treated with 665 and 810 nm laser (but not with 730 or 980 nm) had a significant improvement in Neurological Severity Score that increased over the course of the follow-up compared to sham-treated controls. Morphometry of brain sections showed a reduction in small deficits in 665 and 810 nm laser treated mouse brains at 28 days. CONCLUSIONS: The effectiveness of 810 nm agrees with previous publications, and together with the effectiveness of 660 nm and non-effectiveness of 730 and 980 nm can be explained by the absorption spectrum of cytochrome oxidase, the candidate mitochondrial chromophore in transcranial LLLT.
Authors: Luis De Taboada; Jin Yu; Salim El-Amouri; Sebastiano Gattoni-Celli; Steve Richieri; Thomas McCarthy; Jackson Streeter; Mark S Kindy Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Justin A Zivin; Gregory W Albers; Natan Bornstein; Thomas Chippendale; Bjorn Dahlof; Thomas Devlin; Marc Fisher; Werner Hacke; William Holt; Sanja Ilic; Scott Kasner; Robert Lew; Marshall Nash; Julio Perez; Marilyn Rymer; Peter Schellinger; Dietmar Schneider; Stefan Schwab; Roland Veltkamp; Michael Walker; Jackson Streeter Journal: Stroke Date: 2009-02-20 Impact factor: 7.914
Authors: Yair Lampl; Justin A Zivin; Marc Fisher; Robert Lew; Lennart Welin; Bjorn Dahlof; Peter Borenstein; Bjorn Andersson; Julio Perez; Cesar Caparo; Sanja Ilic; Uri Oron Journal: Stroke Date: 2007-04-26 Impact factor: 7.914
Authors: Margaret A Naeser; Ross Zafonte; Maxine H Krengel; Paula I Martin; Judith Frazier; Michael R Hamblin; Jeffrey A Knight; William P Meehan; Errol H Baker Journal: J Neurotrauma Date: 2014-05-08 Impact factor: 5.269
Authors: Paulo C L Silveira; Karina B Ferreira; Franciani R da Rocha; Bruno L S Pieri; Giulia S Pedroso; Claudio T De Souza; Renata T Nesi; Ricardo A Pinho Journal: Inflammation Date: 2016-08 Impact factor: 4.092